Advantages of Autologous Blood Transfusion in Off-Pump Coronary Artery Bypass
In this randomized controlled study, we investigated the effects of autologous Hemobag blood transfusion (AHBT) and allogenic blood transfusion (ABT) in off-pump coronary artery bypass (OPCAB) surgery.
Methods: Sixty patients who underwent surgery between February 2008 and August 2008 were randomized into 2 groups. The AHBT group (n = 30) consisted of patients who received autologous Hemobag blood transfusion, and the ABT group (n = 30) consisted of patients who received allogenic blood transfusion. All patients underwent OPCAB via sternotomy. The time to extubation, chest tube drainage volume, postoperative white blood cell counts, amount of blood transfusion, sedimentation rate, C-reactive protein concentration, postoperative temperature, and the presence of atelectasis were recorded in the intensive care unit.
Results: Intraoperative bleeding and fluid resuscitation were similar in the 2 groups (P > .05); however, there were significant decreases in postoperative blood loss, extubation period, postoperative white cell counts, sedimentation rate, incidence of atelectasis, C-reactive protein, and fever in the AHBT group compared with the ABT group (P < .05). The rate of atrial fibrillation in the AHBT group tended to be lower than in the ABT group.
Conclusion: Autologous blood transfusion in OPCAB may be beneficial in certain cardiac surgery patients; however, these beneficial effects require further study to be proved.
Allain J-P, Akehurst RL, Hunter JM. 2002. Autologous transfusion, 3 years on: What is new? What has happened? Transfusion 39:910-1.nAronson D, Boulos M, Suleiman A, et al. 2007. Relation of C-reactive protein and new-onset atrial fibrillation in patients with acute myocardial infarction. Am J Cardiol 100:753-7.nAscione R, Williams S, Lloyd CT, Sundaramoorthi T, Pitsis AA, Angelini GD. 2001. Reduced postoperative blood loss and transfusion requirement after beating-heart coronary operations: a prospective randomized study. J Thorac Cardiovasc Surg 121:689-96.nBanbury MK, Brizzio ME, Rajeswaran J, Lytle BW, Blackstone EH. 2006. Transfusion increases the risk of postoperative infection after cardiovascular surgery. J Am Coll Surg 202:131-8.nBryson GL, Laupacis A, Wells GA. 1998. Does acute normovolemic hemodilution reduce perioperative allogeneic transfusion? A meta-analysis. The International Study of Perioperative Transfusion. Anesth Analg 86:9-15.nCasati V, Benussi S, Sandrelli L, Grasso MA, Spagnolo S. 2004. Intraoperative moderate acute normovolemic haemodilution associated with a comprehensive blood-sparing protocol in off-pump coronary surgery. Anesth Analg 98:1217-23.nFeng ZZ, Shi J, Zhao XW, Xu ZF. 2009. Meta-analysis of on-pump and off-pump coronary arterial revascularization. Ann Thorac Surg 87:757-65.nGoodnough LT. 1993. Blood conservation and blood transfusion practices: flip sides of the same coin. Ann Thorac Surg 56:3-4.nGwozdziewicz M, Olsak P, Lonsky V, Elfmark M. 2008. The choice of on- or off-pump coronary bypass grafting: a surgeon's dilemma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152:289-92.nJamnicki M, Kocian R, van der Linden P, Zaugg M, Spahn DR. 2003. Acute normovolemic haemodilution: physiology, limitations, and clinical use. J Cardiothorac Vasc Anesth 17:747-54.nKaramanoukian HL, Panos AL, Bergsland J, Salerno TA. 2000. Perspectives of a cardiac surgery resident in-training on off-pump coronary bypass operation. Ann Thorac Surg 69:42-5.nMack MJ, Brown PP, Kugelmass AD, et al. 2004. Current status and outcomes of coronary revascularization 1999 to 2002: 148,396 surgical and percutaneous procedures. Ann Thorac Surg 77:761-6.nMatot I, Scheinin O, Jurim O, Eid A. 2002. Effectiveness of acute normovolemic haemodilution to minimize allogeneic blood transfusion in major liver resections. Anesthesiology 97:794-800.nPopovsky MA, Devine PA, Taswell HF. 1985. Intraoperative autologous transfusion. Mayo Clin Proc 60:125-34.nPuskas JD, Thourani VH, Marshall JJ, et al. 2001. Clinical outcomes, angiographic patency, and resource utilization in 200 consecutive off-pump coronary bypass patients. Ann Thorac Surg 71:1477-84.nRastan AJ, Eckenstein JI, Hentschel B, et al. 2006. Emergency coronary artery bypass graft surgery for acute coronary syndrome: beating heart versus conventional cardioplegic cardiac arrest strategies. Circulation 114(suppl):I477-85.nRittoo D, Gosling P, Simms MH, Smith SR, Vohra RK. 2005. The effects of hydroxyethyl starch compared with gelofusine on activated endothelium and the systemic inflammatory response following aortic aneurysm repair. Eur J Vasc Endovasc Surg 30:520-4.nSamolyk KA, Beckmann SR, Bissinger RC. 2005. A new practical technique to reduce allogeneic blood exposure and hospital costs while preserving clotting factors after cardiopulmonary bypass: the Hemobag. Perfusion 20:343-9.nScott H, Seifert FC, Grimson R. 2008. Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. Ann Card Anaesth 11:15-9.nSegal JB, Blasco-Colmenares E, Norris EJ, Guallar E. 2004. Preoperative acute normovolemic hemodilution: a meta-analysis. Transfusion 44:632-44.nStaton GW, Williams WH, Mahoney EM, et al. 2005. Pulmonary outcomes of off-pump vs on-pump coronary artery bypass surgery in a randomized trial. Chest 127:892-901.nStehling L, Zauder HL. 1991. Acute normovolemic haemodilution. Transfusion 31:857-68.nTreib J, Haass A, Pindur G, et al. 1995. HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 74:1452-6.nTreib J, Haass A, Pindur G, Treib W, Wenzel E, Schimrigk K. 1996. Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Eur J Haematol 56:168-72.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).